Meta-analysis
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease
- Pooled participant-level analysis of the DAPA-HF and DELIVER randomised trials and trial-level meta-analysis of randomised trials
- placebo-controlled
Authors' conclusion
SGLT2i reduced the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease.
Study context
- Population
- Adults with heart failure (HF) (across the left ventricular ejection fraction (LVEF) spectrum) or other CVD or kidney disease, without diabetes at baselinepooled DAPA-HF and DELIVER
- Participants
- 5,623 adults
- Comparison
- SGLT2i vs placebo
- Outcome
- New-onset diabetes (new initiation of glucose-lowering therapy during follow-up)
Pooled result
New-onset diabetes (pooled DAPA-HF and DELIVER)
Hazard ratio
0.67
95% CI .49-.91
P = 0.012
As reported in the abstract
Further pooled results
| Outcome | HR (95% CI) | P value |
|---|---|---|
| New-onset diabetes, trial-level meta-analysis (7 RCTs, n = 17 855, CVD or kidney disease) · 26% reduction; consistent across trials | 0.74 (.65-.85) | P < 0.001 |
Original publication
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease. Eur Heart J. Published 21 November 2024. doi:10.1093/eurheartj/ehae780
Summarised from the published abstract; every number is checked against it